In the version of this article initially published, there were two typographical errors in the Abstract. The unnecessary 'h' in the line “Furthermore, h according to.....” has been deleted. The line “OSM is thus a potential biomarker of and therapeutic target for IBD,....” was changed to read “OSM is thus a potential biomarker and therapeutic target for IBD...”. These errors have been corrected in the HTML and PDF versions of the article. A coding error that inadvertently resulted in incorrect ordering of the authors in the HTML version was also corrected.
Author information
Consortia
Additional information
The online version of the original article can be found at 10.1038/nm.4307
Rights and permissions
About this article
Cite this article
West, N., Hegazy, A., Owens, B. et al. Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease. Nat Med 23, 788 (2017). https://doi.org/10.1038/nm0617-788d
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0617-788d
This article is cited by
-
Revealing potential drug-disease-gene association patterns for precision medicine
Scientometrics (2021)
-
Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response
Nature Communications (2019)
-
A low-cost paper-based synthetic biology platform for analyzing gut microbiota and host biomarkers
Nature Communications (2018)
-
Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Crohn’s Disease Is Not Associated with Emergence of Novel Inflammatory Pathways
Digestive Diseases and Sciences (2018)
-
Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis
Scientific Reports (2017)
